Article Text

Download PDFPDF

2022-RA-1176-ESGO Borderline ovarien tumor management in a tunisian hospital
  1. Rahma Bouhmida1,
  2. Hajer Bettaieb2,
  3. Meriem Ouederni2,
  4. Nersine Souayeh2,
  5. Hadhami Rouiss2,
  6. Amal Chermiti2,
  7. Hadir Lamiri2,
  8. Wael Mbarki2,
  9. Hedhili Oueslati2 and
  10. Chaouki Mbarki2
  1. 1Gynecology and obstetrics, Regional hospital ben Arous Tunisia, Tunis, Tunisia
  2. 2Gynecology and obstetrics, Regional Hospital Ben Arous, Tunis, Tunisia


Introduction/Background The aim of this study was to determine the epidemiology and clinicopathological characteristics of the borderline ovarian tumors (BOTs). Additionally we sought to characterize the outcomes of the borderline ovarian management and identify variables affecting survival.

Methodology A retrospective study of 49 patients with BOTs all stages taken together treated or referred to our institutions was conducted over a period from June 2016 to july 2021.Data was analyzed by using SPSS Statistics for Windows, Version 23.0.

Results The median age was 43.3 (range=21–61) years. The majority of BOTs was serous tumors (61.2%) followed by mucinous tumors (36.7%) and less common histotypes as Endometrioid borderline tumours (2.1%). In the case of 34 patients (66.7%) a frozen section was taken intraoperatively which matched the definitive histological result in 80,5%. BOTs are mainly diagnosed at an earlier stage (34 cases at FIGO stage IA) 8 patients at stage IB and 3 patients at stage IC on the other hand 2 patients at stage IIIB and finally 2 patients at stage IIIC.All patients underwent surgery. We performed conservative treatment in Nineteen patients (38.7%). It consists of ovarian cystectomy and unilateral adnexectomy . Thirty patients (61.2%) underwent radical treatment which consist of bilateral adnexectomy and hysterectomy.Three patients with BOTs staged IIIB and IIIC received adjuvant chemotherapy. During average follow-up of 5 years 4 patients developed tumor recurrence .

Conclusion Borderline tumours usually affect young women aged between 20 and 40. They are usually diagnosed at an early stage (stage-I disease) . Prognosis is generally excellent, and long-term risk of recurrence is low.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.